Author:
Hayes Daniel Joseph,Banda Clifford George,Chipasula-Teleka Alexandra,Terlouw Dianne Janette
Funder
European & Developing Countries Clinical Trials Partnership
Malaria Control and Elimination Partnership in Africa
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Terlouw DJ, Courval JM, Kolczak MS, Rosenberg OS, Oloo AJ, Kager PA, Lal AA, Nahlen BL, ter Kuile FO. Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in western Kenya. J Infect Dis. 2003;187(3):467–76.
2. WHO. Guidelines for the treatment of malaria. In.; 2010.
3. WHO. The safety and effectiveness of single dose primaquine as a P.falciparum gametocytocide in sub-Saharan Africa, in World Health Organisation Evidence Review Group. In.; 2012.
4. Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother. 2010;54(5):1762–8.
5. Eziefula AC, Pett H, Grignard L, Opus S, Kiggundu M, Kamya MR, Yeung S, Staedke SG, Bousema T, Drakeley C. Glucose-6-phosphate dehydrogenase status and risk of hemolysis in plasmodium falciparum-infected African children receiving single-dose primaquine. Antimicrob Agents Chemother. 2014;58(8):4971–3.